Validea’s guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN) shows it rates highest using the Value Investor model by Benjamin Graham. The stock is a large-cap growth stock in the Biotechnology & Drugs industry, with a rating of 71% based on fundamentals and valuation. The stock meets certain criteria like sales, current ratio, debt ratio, and EPS growth, but fails in P/E and price/book ratio tests. Benjamin Graham, known as the “Father of Value Investing,” has had a lasting impact on the investing world. Validea is an investment research service that follows the strategies of investment legends like Graham.

Read more at Nasdaq: REGN Quantitative Stock Analysis – Benjamin Graham